ERBB3 and cancer: miR-450b-3p binds to the HER3 mRNA to suppress HER3 expression and downstream signaling, subsequently inhibiting breast cancer cell growth and enhancing cancer cell sensitivity to trastuzumab and doxorubicin[164].